Dependence on AMT-130 clinical success
The lead program is a major driver of future value, so failure would materially impair prospects.
- Scope
- Huntington’s disease program
- Materiality
- high
uniQure N.V.
uniQure N.V. is a gene therapy company focused on developing and commercializing treatments for severe genetic and other diseases. Its business centers on adeno-associated virus (AAV) gene therapy programs, including clinical-stage candidates and a marketed therapy, with operations spanning the United States and Europe.
−1 059,7 %
89,5 %
−1 236,0 %
−40,6 %
10.43
10.43
| % | |
|---|---|
| Clinical-stage gene therapy programs | 70% Research, development, and clinical testing of AAV-based therapies for rare and severe diseases. |
| Commercial royalty and license revenue | 20% Royalty and license income tied to HEMGENIX® sales under collaboration arrangements. |
| Collaboration and development services | 10% Services performed for partners under development and supply agreements. |
uniQure’s direct customers are primarily pharmaceutical partners and collaborators, while the eventual end users are...
- Pharmaceutical collaboration partnersprimary
Partners like CSL Behring that buy development, supply, or royalty-linked rights under collaboration agreements.
- Healthcare providers and physiciansprimary
Specialists who recommend and administer gene therapies once products are approved.
- Third-party payersprimary
Insurers and reimbursement bodies that influence access and commercial uptake of approved therapies.
- Patients with rare genetic diseasesprimary
Patients targeted by the company’s gene therapy pipeline, including Huntington’s disease and other rare disorders.
- Clinical and manufacturing service providerssecondary
CROs, CMOs, and other vendors that conduct trials, manufacture materials, and support development.
uniQure operates across the United States and Europe, where it runs clinical development and supports partner-related...
- •Operations and clinical trials span the United States and Europe
- •U.S. regulatory and reimbursement systems are central to commercialization
- •European operations create euro-denominated cost and cash exposure
- •Cross-border clinical work increases regulatory and logistics complexity
- •Foreign exchange movements affect reported results and liquidity
uniQure’s strategy is centered on advancing its lead gene therapy programs through clinical development and regulatory...
01
Advance AMT-130 for Huntington’s diseaseshort-term
The lead program is central to the company’s clinical and commercial value creation.
02
Expand and progress the gene therapy pipelinemedium-term
A broader pipeline reduces dependence on a single asset and supports long-term optionality.
03
Monetize partnered assets and royalty streamsmedium-term
Partnered programs can generate non-dilutive revenue and validate the platform.
04
Manage external execution riskshort-term
Clinical and manufacturing outcomes depend heavily on third-party service providers.
uniQure is highly dependent on the clinical success of AMT-130, so setbacks in efficacy, safety, manufacturing, or...
Third-party execution and data quality risk
CROs and other vendors conduct key studies and supply activities outside direct employee control.
- Scope
- Clinical trials and development programs
- Materiality
- high
Product liability and patient safety claims
Clinical and commercial gene therapies can trigger claims related to adverse events or administration procedures.
- Scope
- Clinical trials and approved products
- Materiality
- high
Healthcare compliance and anti-bribery risk
Commercialization involves physicians, payers, and third parties subject to U.S. and international healthcare laws.
- Scope
- Sales, distribution, and payer arrangements
- Materiality
- medium
Foreign exchange volatility
The company holds and transacts in euros and U.S. dollars, creating translation and remeasurement effects.
- Scope
- Cross-border cash, borrowings, and intercompany balances
- Materiality
- medium
License and collaboration revenue recognition
Can cause uneven quarterly revenue and comparability issues
Contract manufacturing accounting
Affects historical revenue mix and gross margin presentation
Fair value of pre-funded warrants
Can materially affect reported loss in a period
Foreign currency remeasurement
Creates gains or losses unrelated to core operating performance
Contingent consideration
Valuation changes can affect liabilities and earnings
: 29.4.2026